EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 184 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer March 24, 2021 How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... May 21, 2020 How My Navy Career Helped Shape My Positive Attitude During My... December 16, 2020 FDA Approves HPV Tests That Allow for Self-Collection in a Health... July 24, 2024 Load more HOT NEWS Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... How to Find a Caregiver When You Have Cancer
